2-Hydroperoxybutylcyclopropane | 139268-65-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Hydroperoxybutylcyclopropane
• CAS: 139268-65-8
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: ZHYQCBWVGCKTEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Hydroperoxybutylcyclopropane 生成 3,5-Diethyl-1,2-dioxolane
  参考文献：
  名称：

  Mercury(II)-mediated cyclisation of hydroperoxyalkylcyclopropanes: a new route to cyclic peroxides

  摘要：

  Aldehydes, RCHO (R = Me, Et, (i)Pr, and c-C6H11), have been converted via alkylation, cyclopropanation, oxidation, condensation with p-tosylhydrazine, reduction and perhydrolysis into 2-hydroperoxyalkylcyclopropanes, RCH(OOH)CH2c-C3H5, and thence by cycloperoxymercuriation and reductive demercuriation into the corresponding 3-alkyl-5-ethyl-1,2-dioxolanes.

  DOI：

  10.1016/0040-4039(91)80453-d
• 作为产物：
  描述：

  N'-(1-cyclopropylbutan-2-yl)-4-methylbenzenesulfonohydrazide 在 sodium peroxide 、 双氧水 作用下， 生成 2-Hydroperoxybutylcyclopropane
  参考文献：
  名称：

  Mercury(II)-mediated cyclisation of hydroperoxyalkylcyclopropanes: a new route to cyclic peroxides

  摘要：

  Aldehydes, RCHO (R = Me, Et, (i)Pr, and c-C6H11), have been converted via alkylation, cyclopropanation, oxidation, condensation with p-tosylhydrazine, reduction and perhydrolysis into 2-hydroperoxyalkylcyclopropanes, RCH(OOH)CH2c-C3H5, and thence by cycloperoxymercuriation and reductive demercuriation into the corresponding 3-alkyl-5-ethyl-1,2-dioxolanes.

  DOI：

  10.1016/0040-4039(91)80453-d

文献信息

• ORAL IODINE DOSAGE FORM
  申请人：BioPharmX, Inc.

  公开号：US20170304359A1

  公开（公告）日：2017-10-26

  Provided is an oral dosage form comprising a deliverable form of iodine for treating symptoms related to fibrocystic breast condition, for prophylactically maintaining breast health, for treating fibrocystic breasts or breast cancer in pre-menopausal women, for prophylactically maintaining prostate health, and for treating benign prostate hyperplasia along with related methods for making and administering such dosage form. More particularly, this disclosure relates to an oral dosage form that is effective to deliver supraphysiologic levels of molecular iodine. The oral dosage form generally comprises a source of iodine and a reactive agent, wherein the source of iodine and/or the reactive agent are provided in excess.
• [EN] ORAL IODINE DOSAGE FORM<br/>[FR] FORME PHARMACEUTIQUE ORALE D'IODE
  申请人：BIOPHARMX INC

  公开号：WO2017185060A1

  公开（公告）日：2017-10-26

  Provided is an oral dosage form comprising a deliverable form of iodine for treating symptoms related to fibrocystic breast condition, for prophylactically maintaining breast health, for treating fibrocystic breasts or breast cancer in pre-menopausal women, for prophylactically maintaining prostate health, and for treating benign prostate hyperplasia along with related methods for making and administering such dosage form. More particularly, this disclosure relates to an oral dosage form that is effective to deliver supraphysiologic levels of molecular iodine. The oral dosage form generally comprises a source of iodine and a reactive agent, wherein the source of iodine and/or the reactive agent are provided in excess.